A Study to Assess the Safety, Pharmacokinetics, and Potential Effects of Amrubicin on the QT/QTc Interval in Cancer Patients With Advanced Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 02 Apr 2012
At a glance
- Drugs Amrubicin (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- 07 Jul 2011 Actual end date May 2011 added as reported by ClinicalTrials.gov record.
- 07 Jul 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 31 Mar 2011 Planned End Date changed from 1 Mar 2011 to 1 Jun 2011 as reported by ClinicalTrials.gov.